Interview with Anil Raghavan, Country Head – India, Quintiles India
Quintiles first established its operations in India in 1997, which was a very early stage in clinical research. What have been the main changes undergone by the country since then?…
Address: 301 A-Leela Business Park,M.V. Road, Andheri
Mumbai-59,India
Tel: +91 22 5677 4242
Web: http://www.quintiles.com/
Quintiles Transnational is a pharmaceutical services company offering clinical, commercial, consulting and capital services. The Quintiles network consists of more than 20,000 employees in 60 countries.
Quintiles manages clinical trials on behalf of pharmaceutical customers, and provides the following services:
Management of clinical trials, data, projects and providing laboratory services
Providing customers with sales force, product and brand solutions.
Providing data-driven recommendations to help customers achieve success.
Creating strategic partnerships through financing and operational solutions.
Quintiles India is located amidst a rapidly growing local pharmaceutical market. With five offices spread across the country, we help clients take advantage of a well-established corporate infrastructure, government policies favoring R&D, growth in the health insurance sector, and tertiary care and teaching hospitals available for trials.
Other advantages: Quintiles India has solid relationships with leading medical centers and experienced English-speaking investigators. All studies are conducted to FDA and ICH GCP standards. Urban India’s literate population provides fast, efficient access to broad population groups with common and special disease profiles, allowing for rapid patient recruitment and faster study start-ups.
Quintiles helped develop or commercialize all of 2009’s top 50 best selling drugs or compounds and nearly 90% of all breakthrough products released on the market between 1996 and 2008.
Key Services in India:
Access to patients
Biostatistics
Central laboratory services
Clinical monitoring and site management
Data management offering a functional service provider (FSP) business model
Drug safety/pharmacovigilance
ECG monitoring services
Project management
Regulatory services
Phase I/IIa
Access through Our India Team to Quintiles Worldwide:
Consulting services
Partnering
Quintiles first established its operations in India in 1997, which was a very early stage in clinical research. What have been the main changes undergone by the country since then?…
The latest news from the Indian pharma industry, including Dr. Reddy’s purchase of Mayne Pharma’s US portfolio; Sun Pharma’s acquisition of Concert Pharma; Bristol Myers Squibb’s expanded Indian footprint and…
The latest news from the Indian pharma industry, including WHO’s recommendation not to use cough syrup from Marion Biotech after further deaths, Indegene’s expanded presence in Europe, Sun Pharma’s FDA…
The latest news from the Indian pharma sector, including the potential for greater numbers of exports and better market access to the UK under a proposed free trade agreement, yet…
As one of the world’s a leading pharma manufacturers, India supplies about 20 percent of the global pharmaceuticals demand in terms of volume, yet the industry remains plagued with quality…
Top stories from Indian pharma including Dr Reddy’s move to US online platforms, Aspen/Serum Institute’s vaccine deal for Africa, Aurobindo’s USD 37.7 million investment in subsidiary CuraTeQ and Biocon’s FDA…
Arshia Bhandari of patient safety thought leadership forum PhVFIT examines how India is embracing a more patient-centric healthcare model via the implementation of a national patient safety implementation framework. …
The latest healthcare and pharma news from India, including the opening up of COVID-19 vaccine booster shots to all adults; the lowering of vaccine prices; and the licences granted to…
Writing in the March 2022 edition of DIA’s Global Forum magazine, Ananya Chakraborty from the Vydehi Institute of Medical Sciences & Research Centre outlines the key factors behind India’s successful…
The Indian pharma market clocked up double-digit growth of around 15 percent in 2021 (compared to three percent in 2020), driven primarily – but not only – by products related…
The latest news from Indian pharm and healthcare, including Piramal Enterprises’ decision to demerge and list its pharma arm, the country’s 15 pharma billionaires, Danish CNS firm Lundbeck’s decision to…
The latest from Indian pharma, including the year-to-year 51.5 percent growth of the pharma market in April, Lilly’s partnership with three generics makers to expand the availability of its arthritis…
The latest news from Indian pharma, including a 200 percent boost for the country’s pharmaceutical industry in the latest national budget; predictions of rapid growth in the coming decade; Cipla’s…
See our Cookie Privacy Policy Here
